<DOC>
	<DOCNO>NCT00382109</DOCNO>
	<brief_summary>This randomized phase III trial study tacrolimus , methotrexate , sirolimus see well work compare tacrolimus methotrexate prevent graft-versus-host disease young patient undergo donor stem cell transplant intermediate-risk high-risk acute lymphoblastic leukemia second complete remission high risk acute lymphoblastic leukemia first remission . Giving chemotherapy , thiotepa cyclophosphamide , total-body irradiation donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus , methotrexate , sirolimus transplant may stop happen . It yet know whether tacrolimus methotrexate effective without sirolimus prevent graft-versus-host disease .</brief_summary>
	<brief_title>Tacrolimus Methotrexate With Without Sirolimus Preventing Graft-Versus-Host Disease Young Patients Undergoing Donor Stem Cell Transplant Acute Lymphoblastic Leukemia Complete Remission</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare post-transplant 2-year event-free survival pediatric patient intermediate-risk high-risk acute lymphoblastic leukemia ( ALL ) second complete remission high risk ALL first remission undergo allogeneic hematopoietic stem cell transplantation treat graft-versus-host disease ( GVHD ) prophylaxis comprise tacrolimus methotrexate without sirolimus . SECONDARY OBJECTIVES : I . Compare rate relapse , transplant-related mortality , acute chronic GVHD patient . II . Evaluate relative contribution resistance ALL blast cytolytic therapy ( e.g. , chemotherapy/irradiation ) cause relapse post-transplantation correlate ALL vivo blast resistance vivo sirolimus , inhibition level mTOR pathway patient treat sirolimus , alter resistance pathway ALL blast measure microarray analysis . III . Evaluate relative contribution resistance ALL blast donor immune response cause relapse post-transplantation correlating development donor anti-ALL T-cell response , development acute and/or chronic GVHD , detection alter ALL blast immunogenicity transplant increase minimal residual disease , persistent recipient chimerism , relapse . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord specific combination risk ( intermediate CR2 v high CR2 v high CR1 ) , donor type ( match sibling v unrelated relate ) , stem cell source ( filgrastim [ G-CSF ] -primed bone marrow v unprimed bone marrow v bone marrow v peripheral blood v umbilical cord blood ) . PREPARATIVE REGIMEN : Patients undergo total-body irradiation twice daily day -8 -6 receive thiotepa IV day -5 -4 cyclophosphamide IV day -3 -2 . ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION : Patients undergo allogeneic hematopoietic stem cell transplantation day 0 . GRAFT-VERSUS-HOST DISEASE ( GVHD ) PROPHYLAXIS : Patients randomize 1 2 treatment arm . ARM I : ( experimental ) Patients receive tacrolimus IV continuously orally ( able ) daily begin day -2 follow taper begin day 42 continue day 98 ( patient undergo match sibling donor transplantation ) OR tacrolimus IV continuously orally daily begin day -2 follow taper begin day 100 continue day 180 ( patient undergo related , unrelated , cord blood donor transplantation ) absence GVHD . Patients also receive methotrexate IV day 1 , 3 , 6 ( patient match sibling umbilical cord blood donor ) OR day 1 , 3 , 6 , 11 ( patient unrelated bone marrow peripheral blood stem cell donor ) oral sirolimus daily begin day 0 follow taper begin day 180 continue day 207 . ARM II : ( control ) Patients receive tacrolimus methotrexate arm I . After completion study treatment , patient follow periodically approximately 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically cytologically confirm acute lymphoblastic leukemia ( ALL ) second complete remission ( CR2 ) ( M1 bone marrow , &lt; 5 % blast morphology ) meeting follow criterion : Intermediate risk relapse ALL CR2 ( may receive match sibling transplantation ) meeting 1 follow criterion : Blineage ALL CR2 late first bone marrow ( BM ) relapse ( ≥ 36 month initiation primary chemotherapy ) without associate extramedullary disease Blineage ALL CR2 early isolate extramedullary relapse ( &lt; 18 month initiation primary chemotherapy ) High risk relapse ALL CR2 ( may receive related donor , unrelated donor , match sibling transplantation ) meeting 1 follow criterion : In CR2 early first BM relapse ( &lt; 36 month initiation primary chemotherapy ) Tlineage ALL CR2 first BM relapse occur time initiation primary chemotherapy Philadelphia chromosomepositive ALL CR2 first BM relapse occur time initiation primary chemotherapy Tlineage ALL CR2 early isolate extramedullary relapse ( &lt; 18 month initiation primary chemotherapy ) High risk de novo ALL CR1 ( may receive match sibling , related/unrelated BM/PBSC unrelated CB transplantation ) meeting 1 follow criterion : Patients presence ( 9 ; 22 ) translocation ( Ph+ ) detect cytogenetic PCR analysis initial diagnosis . For patient AALL0622 , criterion transplant 1 ) patient Ph+ ALL available match sibling donor 2 ) patient Ph+ ALL define high risk ( MRD &gt; 1 % Day 29 MRD &gt; 0.01 % endConsolidation Block 2 ) available donor , relate unrelated . Patients enrol AALL0622 eligible follow algorithm . Patients presence extreme hypodiploidy ( &lt; 44 chromosome DNA index &lt; 0.81 ) detect cytogenetic/ploidy analysis initial diagnosis . Patients presence 11q23 ( MLL ) rearrangement detect cytogenetic PCR analysis initial diagnosis slow early responder ( M2/M3 Day 14 MRD &gt; 0.1 % Day 29 ) . Enrolled appropriate COG relapse ALL clinical trial completing require study therapy ( i.e. , minimum 1 reinduction course ( 46 week ) 1 round intensive consolidation chemotherapy ( 36 week ) . Patients high risk ALL CR1 eligible soon achieve CR . Patients COG relapse ALL clinical trial eligible provide receive ≥ 1 round reinduction last 46 week 1 round intensive consolidation chemotherapy last 36 week No Bcell ALL L3 morphology evidence myc translocation molecular cytogenetic technique No Down syndrome No evidence active CNS extramedullary disease ( i.e. , CNS2 ) Karnofsky performance status ( PS ) 60100 % ( patient &gt; 16 year age ) OR Lansky PS 60100 % ( patient ≤ 16 year age ) Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 50 % radionuclide angiogram ALT AST &lt; 5 time upper limit normal Bilirubin &lt; 2.5 mg/dL ( unless increase attributable Gilbert 's syndrome ) Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min FEV_1 ≥ 60 % pulmonary function test ( PFTs ) FVC ≥ 60 % PFTs DLCO ≥ 60 % PFTs For child unable cooperate PFTs follow criterion must meet : No evidence dyspnea rest No exercise intolerance No requirement supplemental oxygen therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV uncontrolled fungal , bacterial , viral infection Fungal infection acquire induction therapy allow provided significant response antifungal therapy minimal evidence disease CT scan Other concurrent immunosuppressant allow No prior allogeneic autologous stem cell transplantation No prior concurrent voriconazole unless prior voriconazole therapy complete different agent substitute voriconazole prior study entry No concurrent grapefruit juice sirolimus administration</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>